In Life Sciences, CEO Thomas Joyce noted a strong performance by Beckman Coulter, while in Diagnostics, he said Cepheid grew 25 percent year over year.
The British-based firm says that its assay detects hepatitis C via a single-use, disposable cartridge within 90 minutes of testing.
The grant is specifically intended to support the development of noninvasive, rapid tests that can be used at the point of care in developing country settings.
The firm's life science segment grew revenues 8 percent, but revenues from its diagnostics segment saw revenues retreated 4 percent.
The CE-marked test enables health professionals to distinguish between HIV-1 and HIV-2, and runs on the fully automated Cobas 6800/8800 systems.
The test is the first to be approved for the company's second-generation molecular detection system, but can also be run using the first-generation system alongside other existing assays.
The Medicare contractor proposed coverage for several cancer assays, but would not cover molecular respiratory virus assays or a test for inflammatory bowel disease.
Researches are advancing it mainly for use in mosquito surveillance efforts, but also collected data supporting clinical testing of human samples.
The evidence-based guidelines for testing individuals at risk of latent or active TB infection include recommendations on interferon-gamma release and molecular assays.
Researchers have sequenced and analyzed a genome assembly for a Zika virus reference strain from French Polynesia that might be used as part of diagnostic assays.
With H3Africa, Charles Rotimi has been working to bolster the representation of African participants and African researchers in genomics, Newsweek reports.
NPR reports that government and private insurers are being slow to cover recently approved CAR-T cell therapies.
CNBC reports that there are thousands of genetic tests available for consumers to chose between.
In Nature this week: genomic analysis of ducks, whole-genome doubling among tumor samples, and more.